CN Patent

CN102282128B — 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂

Assigned to AbbVie Inc · Expires 2015-06-17 · 11y expired

What this patent protects

公开的是抑制抗凋亡的Bcl-2蛋白的活性的式(I)的化合物、含有该化合物的组合物和治疗疾病的用途，在该疾病期间，抗凋亡Bcl-2蛋白被表达。式中A 1 、Z 1 、Z 1A 、Z 2 、Z 2A 、L 1 和Z 3 如权利要求书中所定义。

USPTO Abstract

公开的是抑制抗凋亡的Bcl-2蛋白的活性的式(I)的化合物、含有该化合物的组合物和治疗疾病的用途，在该疾病期间，抗凋亡Bcl-2蛋白被表达。式中A 1 、Z 1 、Z 1A 、Z 2 、Z 2A 、L 1 和Z 3 如权利要求书中所定义。

Drugs covered by this patent

Patent Metadata

Patent number
CN102282128B
Jurisdiction
CN
Classification
—
Expires
2015-06-17
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.